Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NUWE

Nuwellis Inc

Jul 26 • 04:00PM ET

2.40

Dollar change -0.10
Percentage change -4.00	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-290.46	Insider Own	0.03%	Shs Outstand	0.19M	Perf Week	-36.84%
Market Cap	0.46M	Forward P/E	-	EPS next Y	-9.45	Insider Trans	0.00%	Shs Float	0.19M	Perf Month	-52.11%
Income	-19.93M	PEG	-	EPS next Q	-7.00	Inst Own	20.01%	Short Float	63.72%	Perf Quarter	-76.27%
Sales	8.89M	P/S	0.05	EPS this Y	91.75%	Inst Trans	-	Short Ratio	0.44	Perf Half Y	-86.01%
Book/sh	4.55	P/B	0.53	EPS next Y	71.58%	ROA	-143.62%	Short Interest	0.12M	Perf Year	-97.44%
Cash/sh	7.37	P/C	0.33	EPS next 5Y	-	ROE	-248.18%	52W Range	2.28 - 98.35	Perf YTD	-88.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	84.44%	ROI	-1449.53%	52W High	-97.56%	Beta	0.49
Dividend TTM	-	Quick Ratio	0.71	Sales past 5Y	12.67%	Gross Margin	57.41%	52W Low	5.26%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	1.20	EPS Y/Y TTM	90.59%	Oper. Margin	-185.81%	RSI (14)	29.27	Volatility	13.73% 19.59%
Employees	59	Debt/Eq	0.80	Sales Y/Y TTM	5.35%	Profit Margin	-224.07%	Recom	3.00	Target Price	52.50
Option/Short	No / No	LT Debt/Eq	0.55	EPS Q/Q	89.53%	Payout	-	Rel Volume	1.80	Prev Close	2.50
Sales Surprise	-7.20%	EPS Surprise	43.40%	Sales Q/Q	1.70%	Earnings	May 07 BMO	Avg Volume	277.07K	Price	2.40
SMA20	-40.12%	SMA50	-62.59%	SMA200	-84.91%	Trades		Volume	498,003	Change	-4.00%

Today 09:00AM	Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE Therapy at Cincinnati Children's (GlobeNewswire)
Jul-24-24 08:02AM	Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -40.00%
Jul-23-24 04:10PM	Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire) +8.36%
Jul-17-24 09:00AM	Nuwellis Marks First Commercial Sale of QUELIMMUNE Therapy to Cincinnati Children's (GlobeNewswire) -6.77%
Jul-12-24 08:30AM	SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner (GlobeNewswire) +8.70%
07:41AM	Loading…
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-09-24 09:00AM	New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference (GlobeNewswire)
Jun-26-24 08:45AM	Nuwellis Announces Reverse Stock Split (GlobeNewswire) -34.25%
Jun-25-24 09:00AM	Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian (GlobeNewswire)
Jun-06-24 09:00AM	Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase (GlobeNewswire)
May-14-24 09:00AM	Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida (GlobeNewswire) -7.17%
May-09-24 09:00AM	Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy (GlobeNewswire) +5.58%
May-07-24 12:53PM	NUWE Stock Earnings: Nuwellis Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +54.04%
08:00AM	Nuwellis, Inc. Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 09:00AM	Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology (GlobeNewswire) +54.89%
06:09PM	Loading…
Apr-30-24 06:09PM	Nuwellis Announces Closing of $2.7 Million Public Offering (GlobeNewswire) +7.22% -13.86%
04:41PM	Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-26-24 09:17AM	Nuwellis Announces Pricing of $2.7 Million Public Offering (GlobeNewswire) -41.94%
Apr-09-24 09:00AM	Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow System at Henry Ford Health (GlobeNewswire)
Mar-07-24 09:08AM	Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Mar-05-24 08:00AM	Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -16.76%
Feb-27-24 09:00AM	Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (GlobeNewswire) -11.26%
Feb-22-24 07:58AM	Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune (GlobeNewswire)
Feb-20-24 05:06PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.41% -11.25%
08:42AM	Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Feb-06-24 09:00AM	New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload (GlobeNewswire) -7.29%
Jan-04-24 03:05PM	Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter (GlobeNewswire) -14.64%
Nov-28-23 08:00AM	New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients (GlobeNewswire)
Nov-14-23 04:30PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-23 01:08PM	Nuwellis, Inc. (NASDAQ:NUWE) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:00AM	Loading…
Nov-07-23 08:00AM	Nuwellis, Inc. Announces Third Quarter 2023 Financial Results (GlobeNewswire) -5.54%
Nov-01-23 08:00AM	Nuwellis Announces Board of Directors Transition (GlobeNewswire) -5.50%
Oct-31-23 08:00AM	Nuwellis' Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device (GlobeNewswire) -8.95%
Oct-18-23 04:15PM	Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) +8.18%
Oct-17-23 04:15PM	Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants (GlobeNewswire) -5.77%
Oct-13-23 08:30AM	Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants (GlobeNewswire) -9.40%
Oct-10-23 08:00AM	Nuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption (GlobeNewswire) -16.94%
Sep-11-23 04:15PM	Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase (GlobeNewswire) -12.50%
Aug-08-23 08:15AM	Nuwellis, Inc. Announces Second Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Nuwellis Announces Plan for CFO Transition (GlobeNewswire)
Jul-18-23 04:15PM	Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jun-20-23 08:30AM	Nuwellis Inc. Announces Pilot Agreement With DaVita Inc. (GlobeNewswire)
Jun-13-23 04:15PM	Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire) +7.27%
Jun-05-23 04:15PM	Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors (GlobeNewswire)
May-22-23 05:10PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-09-23 08:00AM	Nuwellis, Inc. Announces First Quarter 2023 Financial Results (GlobeNewswire) -27.87%
Apr-18-23 08:00AM	Nuwellis, Inc. To Announce First Quarter 2023 Financial Results on May 9, 2023 (GlobeNewswire)
Mar-21-23 08:00AM	Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics (GlobeNewswire)
Mar-01-23 08:00AM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-23 08:00AM	Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -6.05%
Feb-23-23 04:15PM	Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire) +16.15%
08:00AM	Clinical Data Supports the Role of Ultrafiltration in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) (GlobeNewswire)
Feb-07-23 08:00AM	Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023 (GlobeNewswire)
Jan-09-23 08:00AM	Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results (GlobeNewswire) +11.48%
Jan-05-23 02:40PM	Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer (GlobeNewswire) -25.48%
Jan-04-23 05:25PM	Nuwellis, Inc. Announces Passage of Warrant Proposal (GlobeNewswire)
Dec-29-22 01:35PM	SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medicals Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI) (GlobeNewswire) +32.17%
Dec-27-22 04:45PM	Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements (GlobeNewswire) -12.24% +37.48%
Dec-13-22 08:00AM	Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex (GlobeNewswire)
Dec-08-22 08:10AM	Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Nov-30-22 08:00AM	Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -8.27%
Nov-18-22 05:00PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.14% -8.00%
Nov-08-22 08:00AM	Nuwellis, Inc. Reports Third Quarter 2022 Financial Results (GlobeNewswire) -12.21%
Nov-03-22 07:00AM	Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates (GlobeNewswire)
Oct-19-22 04:15PM	Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) -6.09%
07:00AM	Nuwellis Announces Appointment of Chief Financial Officer (GlobeNewswire)
Oct-18-22 04:15PM	Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option (GlobeNewswire) -7.60%
Oct-14-22 08:30AM	Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering (GlobeNewswire) -21.54%
Oct-03-22 07:00AM	Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting (GlobeNewswire) -22.10%
Sep-27-22 07:00AM	Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial (GlobeNewswire)
Aug-31-22 07:00AM	Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients (GlobeNewswire) +131.71%
Aug-25-22 07:00AM	U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology (GlobeNewswire) +7.92%
Aug-19-22 03:00PM	Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Nuwellis Inc. to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-09-22 08:00AM	Nuwellis, Inc. Announces Second Quarter 2022 Financial Results (GlobeNewswire) -8.62%
Jul-26-22 07:00AM	Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA (GlobeNewswire)
Jul-14-22 08:00AM	Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022 (GlobeNewswire)
Jul-12-22 07:00AM	Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy (GlobeNewswire)
Jun-29-22 07:00AM	Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF (GlobeNewswire) +9.91%
Jun-14-22 07:00AM	Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas (GlobeNewswire)
May-17-22 04:25PM	Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) -5.64%
May-10-22 08:00AM	Nuwellis, Inc. Announces First Quarter 2022 Financial Results (GlobeNewswire)
May-09-22 01:11PM	Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting (GlobeNewswire)
Apr-12-22 08:00AM	Nuwellis, Inc. To Announce First Quarter 2022 Financial Results on May 10, 2022 (GlobeNewswire) -8.04%
Mar-15-22 07:00AM	Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study (GlobeNewswire)
Mar-01-22 08:00AM	Nuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-22-22 05:15PM	Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -8.18%
Feb-17-22 08:00AM	Nuwellis Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload (GlobeNewswire)
Feb-01-22 08:00AM	Nuwellis, Inc. to Announce Fourth Quarter 2021 Financial Results on March 1, 2022 (GlobeNewswire)
Jan-25-22 08:00AM	New Category III CPT Code for the Nuwellis Aquadex Ultrafiltration System is Now in Effect (GlobeNewswire) +5.11%
Nov-19-21 04:00PM	Nuwellis, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.74%
Nov-09-21 08:00AM	Nuwellis, Inc. Announces Third Quarter 2021 Financial Results (GlobeNewswire) -9.58%
Nov-04-21 08:00AM	Aquadex SmartFlow® System by Nuwellis Selected as a 2021 R&D 100 Awards Winner (GlobeNewswire)
Oct-19-21 08:00AM	Nuwellis Selected as a Recipient of the Governors International Trade Award (GlobeNewswire)
Oct-14-21 04:03PM	Nuwellis, Inc. To Announce Third Quarter 2021 Financial Results on November 9, 2021 (GlobeNewswire)
Sep-21-21 08:00AM	Nuwellis Receives CE Mark for 24-Hour Blood Circuit Set (GlobeNewswire)
Sep-17-21 04:00PM	Nuwellis, Inc. Announces Closing of $10.0 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option (GlobeNewswire) -6.15%
Sep-15-21 08:19AM	Nuwellis, Inc. Announces Pricing of $8.7 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -27.64%
Sep-14-21 04:03PM	Nuwellis, Inc. Announces Proposed Underwritten Public Offering of Common Stock (GlobeNewswire) -8.21%
08:00AM	Nuwellis, Inc. Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NUWE

Nuwellis Inc

Upgrade your FINVIZ experience